Y-mAbs Therapeutics
YMAB
Market cap $186M

4.25 USD

+0.05

1.19%

At close Apr 30, 4:00 PM EDT

After hours

4.25

+0.00

0.00%

1 day

1.19%

5 days

6.52%

1 month

-4.06%

3 months

-31.34%

6 months

-71.38%

Year to date

-46.68%

1 year

-72.06%

5 years

-87.34%

10 years

-82.29%

About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Employees: 107

Healthcare Biotechnology

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

525% more call options, than puts

Call options by funds: $50K | Put options by funds: $8K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

6.45% more ownership

Funds ownership: 57.75% [Q3] → 64.2% (+6.45%) [Q4]

6% more funds holding

Funds holding: 105 [Q3] → 111 (+6) [Q4]

33% less capital invested

Capital invested by funds: $339M [Q3] → $225M (-$113M) [Q4]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

65%

upside

Avg. target

$12.25

188%

upside

High target

$18

324%

upside

4 analyst ratings

2 positive

50%

1 neutral

25%

1 negative

25%

HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 172 met price target	182%upside $12	Buy Maintained	21 Mar 2025
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 8 met price target	182%upside $12	Neutral Maintained	5 Mar 2025
Truist Securities Nicole Germino 42% 1-year accuracy 5 / 12 met price target	324%upside $18	Buy Maintained	5 Mar 2025
Morgan Stanley Michael Ulz 32% 1-year accuracy 6 / 19 met price target	65%upside $7	Underweight Maintained	5 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about YMAB published over the past 30 days

Negative

Zacks Investment Research

1 day ago

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neutral

GlobeNewsWire

3 days ago

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL.

Neutral

GlobeNewsWire

5 days ago

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial evaluating the Company's Self-Assembly and Disassembly (“SADA”) Pre-targeted Radioimmunotherapy (“PRIT”) platform for the treatment of patients with relapsed or refractory non-Hodgkin Lymphoma (r/r NHL). This Phase 1 trial (Trial 1201) is a dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex.

$Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma$